Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Liabilities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Other Non-Current Liabilities data on record, last reported at $1.9 million in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 38.56% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, down 38.56%, while the annual FY2024 figure was $2.5 million, 49.26% down from the prior year.
  • Other Non-Current Liabilities reached $1.9 million in Q3 2025 per STOK's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $4.9 million in Q4 2023 and bottomed at $959000.0 in Q3 2023.
  • Average Other Non-Current Liabilities over 4 years is $2.8 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 73.43% in 2023, then surged 218.04% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $3.0 million in 2022, then surged by 64.56% to $4.9 million in 2023, then tumbled by 49.26% to $2.5 million in 2024, then decreased by 24.37% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $1.9 million in Q3 2025, $1.3 million in Q2 2025, and $1.9 million in Q1 2025.